Date:
In a phase 2 trial involving participants taking a nucleoside or nucleotide analogue, 23% of those assigned to receive xalnesiran plus pegylated interferon alfa-2a had HBsAg loss at 24 weeks after the end of treatment.
The New England Journal of Medicine: Search Results in Infectious Disease
Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click.
© 2021 tagDiv. All Rights Reserved. Made with Newspaper Theme.
